Inozyme Pharma, Inc. recently reported promising data from Phase 1/2 clinical trials of their drug INZ-701.

Cynata Therapeutics has successfully completed patient recruitment for its Phase 1 clinical trial of CYP-006TK, a treatment for diabetic foot ulcers (DFU).

The trial focused on MT-601, a novel T cell therapy targeting various tumor antigens, and was well-tolerated by participants, leading to sustained objective responses.

CytomX Therapeutics has initiated a Phase 1 clinical trial for CX-2051, an antibody drug conjugate (ADC) aimed at treating advanced solid tumors.

Oryzon Genomics, a biopharmaceutical firm specializing in epigenetic therapies for diseases with significant medical needs, has received approval from the U.S. FDA to begin a Phase I/II clinical trial.

Encouraging initial findings indicate that individuals with relapsed or refractory multiple myeloma, who experienced progression post BCMA-directed treatments, have shown clinical improvements with P-BCMA-ALLO1, demonstrating a good safety profile.

New findings reveal that zerlasiran, an innovative therapeutic developed by Silence Therapeutics plc, effectively reduces lipoprotein(a) (Lp(a)) levels and is well-tolerated in both single and multiple doses.

The Phase 1/2 KRYSTAL-1 trial, sponsored by Mirati Therapeutics, Inc., a subsidiary of Bristol Myers Squibb, combined KRAZATI® (adagrasib) with cetuximab to treat this specific group of patients who had undergone prior treatment.

Seres Therapeutics, a pioneering company in the field of microbiome therapeutics, has recently announced the completion of enrollment for Cohort 2 in its Phase 1b clinical trial of SER-155.

Alkermes plc has reported positive findings from a phase 1b study of ALKS 2680, an oral orexin 2 receptor agonist, in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).

Medicenna Therapeutics Corp. has reported positive interim results from its Phase 1/2 ABILITY-1 study of MDNA11, a long-acting interleukin-2 (IL-2) super-agonist.

In a recent clinical trial, 20 patients suffering from relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) were administered a combination treatment of evorpacept, rituximab, and lenalidomide, commonly referred to as the "R2" regimen.